P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies.
Laurent Dercle,Laurent Dercle,Fatima-Zohra Mokrane,Jean Marc Schiano de Colella,Apasia Stamatoullas,Franck Morschhauser,Pauline Brice,Hervé Ghesquières,Olivier Casasnovas,Aiping Chen,Guillaume Manson,Roch Houot +11 more
TL;DR: Early pseudo-progressive lesions did not significantly alter response evaluation since they were all observed in unequivocally progressive patients, and the most significant encountered problems were mixed responses and irAEs.
Journal ArticleDOI
B-cell lymphomas involving the skin associated with hepatitis C virus infection.
Manuelle Viguier,Jacqueline Rivet,Félix Agbalika,Ericde Kerviler,Pauline Brice,Louis Dubertret,Hervé Bachelez +6 more
TL;DR: A role for hepatitis C virus infection has been suggested in the pathogenesis of non‐Hodgkin lymphomas (NHL) and this work aims to establish a causal relationship between HCV infection and NHL.
Journal ArticleDOI
Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis
Luc Xerri,Emmanuel Bachy,Bettina Fabiani,Danielle Canioni,Catherine Chassagne-Clément,Peggy Dartigues-Cuillères,Frédéric Charlotte,Nicole Brousse,Marie-Christine Rousselet,Charles Foussard,Pauline Brice,Pierre Feugier,F. Morschhauser,Anne Sonet,Daniel Olive,Gilles Salles +15 more
TL;DR: MUM1 is a strong and robust predictive immunohistochemical marker in patients with FL and is associated with a shorter progression-free survival in the FL2000 cohort.
Journal ArticleDOI
Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.
Hervé Ghesquières,Matthew J. Maurer,Olivier Casasnovas,Stephen M. Ansell,Beth R. Larrabee,Eva Lech-Maranda,Anne J. Novak,Anne Laure Borrel,Susan L. Slager,Pauline Brice,Cristine Allmer,Annie Brion,Steven C. Ziesmer,Franck Morschhauser,Thomas M. Habermann,Isabelle Gaillard,Brian K. Link,Aspasia Stamatoullas,Christophe Fermé,Ahmet Dogan,William R. Macon,Josée Audouin,James R. Cerhan,Gilles Salles +23 more
TL;DR: This study showed that germline variation in TNFA was associated with CHL prognosis for EBV-negative patients, which will require confirmation, and support broader studies on the differential impact of genetic variation in immune genes onEBV-positive vs. EBv-negative CHL pathogenesis.
Journal ArticleDOI
Classical Hodgkin lymphoma
TL;DR: For example, this paper showed that the median age of patients with classical Hodgkin lymphoma is in the mid-30s and the disease's impact on the number of years lost from productive life is remarkable.